Results 141 to 150 of about 4,277 (167)
CAMEO-a cross-sectional survey study on candidemia management in Germany. [PDF]
Reinhold I +8 more
europepmc +1 more source
Tinea corporis and tinea cruris incidence, risk factors, and treatments in a cohort of 6.8 million patients with Medicaid, United States. [PDF]
Sajewski ET +4 more
europepmc +1 more source
Comprehensive study on in vitro propagation of some imported peach rootstocks b. In vitro rooting and acclimatization. [PDF]
Eliwa GI +3 more
europepmc +1 more source
The in vitro activity of iron chelator deferiprone against Candida (Candidozyma) auris in combination with antifungal agents. [PDF]
Tóth Z +7 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Lancet Haematology,the, 2020
The phase 3 GIMEMA-MMY-3006 trial, which compared bortezomib, thalidomide, and dexamethasone (VTD) combination therapy with thalidomide and dexamethasone (TD) as induction therapy before and consolidation therapy after double autologous haematopoietic stem-cell transplantation (HSCT) for newly diagnosed multiple myeloma, showed the superiority of the ...
Mario Boccadoro +2 more
exaly +8 more sources
The phase 3 GIMEMA-MMY-3006 trial, which compared bortezomib, thalidomide, and dexamethasone (VTD) combination therapy with thalidomide and dexamethasone (TD) as induction therapy before and consolidation therapy after double autologous haematopoietic stem-cell transplantation (HSCT) for newly diagnosed multiple myeloma, showed the superiority of the ...
Mario Boccadoro +2 more
exaly +8 more sources
Multiple Myeloma Mortality Incidence Prevalence of Disease - Mmy Mind Study
Blood, 2020Background Multiple myeloma (MM) is a heterogeneous and incurable disease that evolves from asymptomatic premalignant conditions. The worldwide incidence, prevalence and mortality are well known thanks to data reported by the International Agency for Research on Cancer (IARC) and by the GLOBOCAN World Cancer Observatory.
Humberto Martínez Cordero +11 more
openaire +1 more source
Blood, 2010
Abstract Abstract 312 Background: Bortezomib (VELCADE®) is approved in the US and Europe for the treatment of patients with multiple myeloma (MM) in both the frontline and the relapse settings.
Moreau, Philippe +17 more
openaire +2 more sources
Abstract Abstract 312 Background: Bortezomib (VELCADE®) is approved in the US and Europe for the treatment of patients with multiple myeloma (MM) in both the frontline and the relapse settings.
Moreau, Philippe +17 more
openaire +2 more sources

